Alzheimer’s testing technology licensed to Takeda in $87 million deal
A new Alzheimer's disease biomarker test developed by Durham, North Carolina-based Zinfandel Pharmaceuticals is licensed by Takeda Pharmaceutical Co. in a deal worth up to $87 million.